A 34-year-old cisgender woman with HIV was started on bictegravir-tenofovir alafenamide-emtricitabine 18 months ago. She had virologic suppression after 2 months and has maintained HIV RNA levels that are undetectable. Her baseline HIV RNA level was 74,328 copies/mL, and HIV drug resistance genotypic testing showed no mutations. She is concerned that she has gained 14 pounds on this regimen and is asking to take the fewest possible pills. She has received hepatitis B vaccine and is immune to hepatitis B virus (HBV).